In Q4 2025, AstraZeneca reported total revenue of $15.50bn with strong contributions from Oncology and BioPharmaceuticals. Reported operating profit rose sharply year over year, and EPS growth reflected continued commercial momentum across core franchises.

AstraZeneca delivered robust financials in Q3 2025, posting $15.19 billion in revenue and a 64% increase in operating profit. The company continued to benefit from strong demand in oncology, respiratory, and cardiovascular portfolios.

AstraZeneca delivered a strong Q2 2025 with $14.46 billion in revenue and $3.5 billion in net income. The company saw continued growth in its oncology, biopharmaceuticals, and rare disease portfolios, supported by new molecular entities entering Phase III trials.

AstraZeneca posted a strong Q1 2025 with double-digit revenue growth driven by Oncology and BioPharmaceuticals, alongside five positive Phase III study readouts and expanded US manufacturing investments.